Abstract
Prostate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer death in western men, and as such constitutes a significant health problem. The male sex steroids, androgens, have long been recognized as major contributors to the progression of PCa. Still today, standard therapy for PCa is aimed at removing androgens and/or blocking the action of androgens. Although most PCas initially regress following anti-androgen therapy, a majority of these tumors eventually start to regrow, leaving the patient very little hope of curative treatment. Interestingly, in androgen-refractory PCas the androgen receptor (AR), the transcription factor mediating the effects of androgens, continues to be expressed, and AR signaling remains functional. Moreover, disruption of the activity or the expression of the AR inhibits proliferation of androgen-refractory PCa cells, emphasizing that, in the androgen-independent state of the disease, ARmediated signaling is crucial to the survival of PCa cells. Several potential mechanisms, most likely not mutually exclusive, have been described to account for activation of the AR in androgen-refractory PCa cells. Recent reports of aberrant expression of coregulators that are required for the formation of productive AR transcriptional complexes in androgen-refractory PCa and its correlation with PCa disease progression, have enhanced interest into this mechanism and have led to the proposition of AR coregulator protein complexes as potential novel targets for PCa therapy. This review seeks to critically analyze the current knowledge on AR coregulator expression in PCa tissues and to evaluate how this information could translate into novel therapeutic targets for PCa.
Keywords: androgen receptor, prostate cancer, coregulatory protein, coactivator, corepressor
Current Cancer Therapy Reviews
Title: Androgen Receptor Coregulatory Proteins as Potential Therapeutic Targets in the Treatment of Prostate Cancer
Volume: 1 Issue: 2
Author(s): Hannelore V. Heemers and Donald J. Tindall
Affiliation:
Keywords: androgen receptor, prostate cancer, coregulatory protein, coactivator, corepressor
Abstract: Prostate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer death in western men, and as such constitutes a significant health problem. The male sex steroids, androgens, have long been recognized as major contributors to the progression of PCa. Still today, standard therapy for PCa is aimed at removing androgens and/or blocking the action of androgens. Although most PCas initially regress following anti-androgen therapy, a majority of these tumors eventually start to regrow, leaving the patient very little hope of curative treatment. Interestingly, in androgen-refractory PCas the androgen receptor (AR), the transcription factor mediating the effects of androgens, continues to be expressed, and AR signaling remains functional. Moreover, disruption of the activity or the expression of the AR inhibits proliferation of androgen-refractory PCa cells, emphasizing that, in the androgen-independent state of the disease, ARmediated signaling is crucial to the survival of PCa cells. Several potential mechanisms, most likely not mutually exclusive, have been described to account for activation of the AR in androgen-refractory PCa cells. Recent reports of aberrant expression of coregulators that are required for the formation of productive AR transcriptional complexes in androgen-refractory PCa and its correlation with PCa disease progression, have enhanced interest into this mechanism and have led to the proposition of AR coregulator protein complexes as potential novel targets for PCa therapy. This review seeks to critically analyze the current knowledge on AR coregulator expression in PCa tissues and to evaluate how this information could translate into novel therapeutic targets for PCa.
Export Options
About this article
Cite this article as:
Heemers V. Hannelore and Tindall J. Donald, Androgen Receptor Coregulatory Proteins as Potential Therapeutic Targets in the Treatment of Prostate Cancer, Current Cancer Therapy Reviews 2005; 1 (2) . https://dx.doi.org/10.2174/1573394054021745
DOI https://dx.doi.org/10.2174/1573394054021745 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews Osteoimmunology and Beyond
Current Medicinal Chemistry Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine Editorial {Hot topic: QSPR Models for Computer-Aided Drug Design in Microbiology, Parasitology, and Pharmacology (Guest Editor: Humberto Gonzalez-Diaz)]
Current Computer-Aided Drug Design Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC)
Reviews on Recent Clinical Trials In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine Construction and Validation of a Nomogram for Predicting Progression- Free Survival in Patients with Early-Stage Testicular Germ Cell Tumor
Recent Patents on Anti-Cancer Drug Discovery Recent Development in the Synthesis of Eco-Friendly Polymeric Antioxidants
Current Organic Chemistry Endocytosis, Intracellular Traffic and Fate of Cell Penetrating Peptide Based Conjugates and Nanoparticles
Current Pharmaceutical Design Immunotherapy and Cancer Vaccines in the Management of Breast Cancer
Current Pharmaceutical Design Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma
Mini-Reviews in Medicinal Chemistry Gold Nanoparticles as Carrier(s) for Drug Targeting and Imaging
Pharmaceutical Nanotechnology Differential Serum Level of Specific Haptoglobin Isoforms in Small Cell Lung Cancer
Current Proteomics Retroviral Gene Therapy: Safety Issues and Possible Solutions
Current Gene Therapy New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Drugs in Bone Loss-Associated Disorders: Clinical Outcomes and Challenges
Current Drug Targets Further Vitamin D Analogs
Current Vascular Pharmacology Proteasome Inhibition: A Promising Strategy for Treating Cancer, but What About Neurotoxicity?
Current Medicinal Chemistry Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain
Current Gene Therapy Targeting Apoptosis Pathways in Cancer Therapy
Current Cancer Drug Targets